Merck Says 776-Patient sac-TMT Trial Extends Survival in Advanced Endometrial Cancer
Updated
Updated · Fox News · May 20
Merck Says 776-Patient sac-TMT Trial Extends Survival in Advanced Endometrial Cancer
8 articles · Updated · Fox News · May 20
Merck said its investigational drug sacituzumab tirumotecan met Phase 3 goals for both overall survival and progression-free survival in advanced or recurrent endometrial cancer after prior platinum chemotherapy and immunotherapy.
The TroFuse-005 study randomized 776 patients to sac-TMT every two weeks or physician’s-choice chemotherapy, and Merck said the drug also improved response rates with side effects similar to earlier studies.
Researchers called it the first global Phase 3 trial to show statistically significant survival gains over chemotherapy in this setting, and the first antibody-drug conjugate to do so for endometrial cancer.
Merck did not release exact survival, response-rate or toxicity figures, leaving the magnitude of benefit and safety profile to be clarified when full data are presented at a medical meeting.
The result targets a growing unmet need in a cancer whose incidence and mortality are rising, with one trial investigator noting U.S. endometrial cancer deaths now exceed ovarian cancer deaths.
How will this Chinese-developed drug's success reshape the global cancer treatment market?
Could this new drug truly replace chemotherapy for endometrial cancer, as some analysts predict?
With a new FDA program promising two-month reviews, what safety assurances will patients have?
Sacituzumab Tirumotecan Achieves Landmark 32% Reduction in Mortality: TroFuse-005 Phase 3 Results Set New Standard for Advanced Endometrial Cancer
Overview
The Phase 3 TroFuse-005 trial marks a major advance for patients with advanced or recurrent endometrial cancer, showing that sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate, is the first in its class to deliver statistically significant and clinically meaningful improvements in both overall survival and progression-free survival. These results represent a significant leap forward, offering new hope to patients who have limited treatment options after previous therapies. The success of sac-TMT in this trial sets a new benchmark for care and highlights its potential to transform the treatment landscape for this challenging disease.